Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis

Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis

(2016) Franck Carbonnel et al.   GASTROENTEROLOGY

Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact

(2016) Richard N Fedorak et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's disease

(2014) C. Ma et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Four-Year Maintenance Treatment With Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis: Data from ULTRA 1, 2 and 3

(2014) Jean-Frederic Colombel et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Real-life Treatment Paradigms Show Infliximab Is Cost-effective for Management of Ulcerative Colitis

(2014) Victoria Ung et al.   Clinical Gastroenterology and Hepatology

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants

(2013) Walter Reinisch et al.   INFLAMMATORY BOWEL DISEASES

Efficacy of adalimumab rescue therapy in patients with chronic refractory pouchitis previously treated with infliximab

(2012) Manuel Barreiro-de Acosta et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis

(2012) Edel McDermott et al.   Journal of Crohns & Colitis

Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn's patients

(2012) Filip Baert et al.   Journal of Crohns & Colitis

Long-Term Direct Costs Before and After Proctocolectomy for Ulcerative Colitis: A Population-Based Study in Olmsted County, Minnesota

(2011) Stefan D. Holubar et al.   DISEASES OF THE COLON & RECTUM

Long-Term Adjustment to Living With an Ileal Pouch-Anal Anastomosis

(2011) Ina E. Berndtsson et al.   DISEASES OF THE COLON & RECTUM

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

(2011) William J. Sandborn et al.   GASTROENTEROLOGY

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial

(2011) W. Reinisch et al.   GUT

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease

(2011) Gord Blackhouse et al.   Journal of Crohns & Colitis

Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab

(2010) C. Taxonera et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort

(2010) N. Gies et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Quality of life, health-related quality of life and health status in patients having restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis: a systematic review

(2010) J. T. Heikens et al.   Colorectal Disease

M1085 Use of Infliximab and Adalimumab in Refractory Pouchitis

(2010) Paolo Gionchetti et al.   GASTROENTEROLOGY

Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data

(2009) K. BODGER et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease

(2009) Edward V. Loftus et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab

(2009) Waqqas Afif et al.   INFLAMMATORY BOWEL DISEASES

The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use

(2009) Stephanie C. Manson et al.   RESPIRATORY MEDICINE

Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience

(2008) A. OUSSALAH et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

(2008) Brian G. Feagan et al.   GASTROENTEROLOGY

Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease

(2008) Lisa M. Lix et al.   INFLAMMATORY BOWEL DISEASES

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

(2008) E.F. Stange et al.   Journal of Crohns & Colitis

The Role of Economic Evidence in Canadian Oncology Reimbursement Decision-Making: To Lambda and Beyond

(2008) Angela Rocchi et al.   VALUE IN HEALTH

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research